Novo Nordisk is developing an oral replacement therapy drug called NN1952 for patients with type 1 and 2 diabetes. The drug is a fast-acting oral insulin analogue and would be the first of its class. Novo Nordisk plans to increase awareness of diabetes and their new drug through social media campaigns and by launching a website and mobile app to provide diabetes patients information, support, and tools to better manage their condition. The goal is to help more diabetics properly manage their disease and medication through reducing barriers like embarrassment of injections or lack of information.